01/25/23 6:00 AMNasdaq : IMRN low floatImmuron US DoD Naval Medical Research Center responds to FDA Clinical Hold for New Campylobacter ETEC TherapeuticImmuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, todayRHEA-AIneutral
01/18/23 5:00 AMNasdaq : IMRN low floatUS Department of Defense Uniformed Services University Clinical Evaluation of Travelan™ Achieves 150 Recruitment MilestoneHighlights: First participants enrolled in USU Travelan Clinical Trial Field Study 157 participants successfully randomized into the Clinical Study Plans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnelRHEA-AIneutral
01/17/23 7:10 AMNasdaq : IMRN low floatImmuron Receives European Patent on Drug Composition to Treat Clostridioides difficile Associated DiseaseImmuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, isRHEA-AIvery positive
12/23/22 6:00 AMNasdaq : IMRN fda approvallow floatImmuron Receives FDA Approval for Travelan IND ApplicationHighlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active Plans in place to initiate a Human clinicalRHEA-AIneutral
12/05/22 6:00 AMNasdaq : IMRN low floatImmuron Submits IND Application To FDA for TravelanHighlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US militaryRHEA-AIneutral
11/16/22 7:00 AMNasdaq : IMRN low floatImmuron completes strategic investment in leading gut health biotech Ateria HealthHighlights: Immuron has completed settlement of strategic investment in leading gut health biotech Ateria Health, in accordance with signed subscription and option agreement (announced 13 October 2022): Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of AteriaRHEA-AIvery positive
10/26/22 6:00 AMNasdaq : IMRN conferenceslow floatImmuron CEO, Steven Lydeamore to present at AusBioInvestImmuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases; isRHEA-AIneutral
10/13/22 6:00 AMNasdaq : IMRN low floatImmuron strategic investment in leading gut health biotech Ateria HealthHighlights: Immuron has signed a subscription and option agreement with leading gut health biotech Ateria Health: Strategic investment of approximately £1.5m (A$2.6m) to acquire an initial 17.5% of Ateria Health; Option for further investment of £1.47m, expiring on 31 July 2023 Ateria Health is aRHEA-AIvery positive
10/04/22 6:00 AMNasdaq : IMRN clinical triallow floatImmuron Executes Travelan Clinical Trial Agreement with US-based PharmaronHighlights: Clinical Trial Master Service Agreement with US-based Pharmaron Executed Investigational New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy volunteersRHEA-AIneutral
08/29/22 7:00 AMNasdaq : IMRN conferenceslow floatImmuron CEO, Steven Lydeamore, to host an investor webinarImmuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invites investors to join a live webcast hostedRHEA-AIneutral